Prof. Dr. Max Keller
Institut für Pharmazie
Universität Regensburg

Publikationen in Publikationsorganen mit wissenschaftlicher Qualitätssicherung

(**Corresponding Author*)

2025

(63) Schettler, F.; Gattor, A. O.; Koch, P.; Keller, M.* Characterization of [^{3}H]propionylated human peptide YY - a new probe for neuropeptide Y Y_2 receptor binding studies. *ACS Pharmacol. Transl. Sci.* **2025**, *in press*.

(62) Schorr, K.; Beck, S.; Zimmer, O.; Baumann, F.; Keller, M.; Witzgall, R.; Goepferich, A.* The quantity of ligand–receptor interactions between nanoparticles and target cells. *Nanoscale Horiz.* **2025**, *in press*.

2024

(61) Märkl, S.; Przybilla, F.; Rachel, R.; Hirsch, T.; Keller, M.; Witzgall, R.; Mely, Y.; Wegener, J.* Impact of surface chemistry of upconversion nanoparticles on time-dependent cytotoxicity in non-cancerous epithelial cells. *Sci. Rep.* **2024**, *14*, 30610.

(60) Ertl, F. J.; Kopanchuk, S.; Dijon, N. C.; Veiksina, S.; Tahk, M. J.; Laasfeld, T.; Schettler, F.; Gattor, A. O.; Hubner, H.; Archipowa, N.; Kockenberger, J.; Heinrich, M. R.; Gmeiner, P.; Kutta, R. J.; Holliday, N. D.*; Rinken, A.*; Keller, M.* Dually labeled neurotensin NTS_1R ligands for probing radiochemical and fluorescence-based binding assays. *J. Med. Chem.* **2024**, *67*, 16664-16691.

(59) Banjarnahor, S.; Scherpinski, L. A.; Keller, M.; Konig, J.; Maas, R.* Differential uptake of arginine derivatives by the human heteromeric amino acid transporter b(0,+)AT-rBAT (SLC7A9-SLC3A1). *Naunyn-Schmiedeberg's Arch. Pharmacol.* **2024**, *in press*.

(58) Rayo Abella, L. M.; Jacob, H.; Hesse, C.; Hofmann, B.; Schneider, S.; Schindler, L.; Keller, M.; Buchwalow, I. B.; Jin, C.; Panula, P.; Dhein, S.; Klimas, J.; Hadova, K.; Gergs, U.; Neumann, J.* Initial characterization of a transgenic mouse with overexpression of the human D(1)-dopamine receptor in the heart. *Naunyn-Schmiedeberg's Arch. Pharmacol.* **2024**, *397*, 4939-4959.

(57) Rayo Abella, L. M.; Jacob, H.; Keller, M.; Schindler, L.; Pockes, S.; Pitzl, S.; Klimas, J.; Hadova, K.; Schneider, S.; Buchwalow, I. B.; Jin, C.; Panula, P.; Kirchhefer, U.; Neumann, J.; Gergs, U.* Initial characterization of a transgenic mouse with overexpression of the human H(1)-histamine receptor on the heart. *J. Pharmacol. Exp. Ther.* **2024**, *389*, 174-185.

(56) Calderon, J. C.; Plut, E.; Keller, M.; Cabrele, C.; Reiser, O.; Gervasio, F. L.; Clark, T.* Extended metadynamics protocol for binding/unbinding free energies of peptide ligands to class A G-protein-coupled receptors. *J. Chem. Inf. Model.* **2024**, *64*, 205-218.

(55) Gleixner, J.; Kopanchuk, S.; Gratz, L.; Tahk, M. J.; Laasfeld, T.; Veiksina, S.; Horing, C.; Gattor, A. O.; Humphrys, L. J.; Muller, C.; Archipowa, N.; Kockenberger, J.; Heinrich, M. R.; Kutta, R. J.; Rinken, A.*; Keller, M.* Illuminating neuropeptide Y Y(4) receptor binding: fluorescent cyclic peptides with subnanomolar binding affinity as novel molecular tools. *ACS Pharmacol. Transl. Sci.* **2024**, *7*, 1142-1168.

2023

(54) Archipowa, N.; Wittmann, L.; Kockenberger, J.; Ertl, F. J.; Gleixner, J.; Keller, M.*; Heinrich, M. R.*; Kutta, R. J.* Characterization of fluorescent dyes frequently used for bioimaging: photophysics and photocatalytical reactions with proteins. *J. Phys. Chem.* B **2023**, *127*, 9532-9542.

(53) Gleixner, J.; Gattor, A. O.; Humphrys, L. J.; Brunner, T.; Keller, M.* [^{3}H]UR-JG102 - a radiolabeled cyclic peptide with high affinity and excellent selectivity for the neuropeptide Y Y_4 receptor. *J. Med. Chem.* **2023**, *66*, 13788-13808.

(52) Plut, E.; Calderón, J. C.; Stanojlović, V.; Gattor, A. O.; Höring, C.; Humphrys, L. J.; Konieczny, A.; Kerres, S.; Schubert, M.; Keller, M.*; Cabrele, C.*; Clark, T.*; Reiser O.* Stereochemistry-driven interactions of α,γ-peptide ligands with the neuropeptide Y Y_4-receptor. *J. Med. Chem.* **2023**, *66*, 9642-9657.

(51) Wirth, U.; Erl, J.; Azzam, S.; Höring, C.; Skiba, M.; Singh, R.; Hochmuth, K.; Keller, M.*; Wegener, J.*; König, B.* Monitoring the reversibility of GPCR signaling by combining photochromic ligands with label-free impedance analysis. *Angew. Chem., Int. Ed*. **2023**, *62*, e202215547.

2022

(50) Köckenberger, J.; Fischer, O.; Konopa, A.; Bergwinkl, S.; Mühlich, S.; Gmeiner, P.; Kutta, R. J.; Hubner, H.; Keller, M.; Heinrich, M. R.* Synthesis, characterization, and application of muscarinergic M(3) receptor ligands linked to fluorescent dyes. *J. Med. Chem.* **2022**, *65*, 16494-16509.

(49) Schindler, L.; Moosbauer, J.; Schmidt, D.; Spruss, T.; Gratz, L.; Lüdeke, S.; Hofheinz, F.; Meister, S.; Echtenacher, B.; Bernhardt, G.; Pietzsch, J.; Hellwig, D.; Keller, M.* Development of a neurotensin-derived ^{68}Ga-labeled PET ligand with high in vivo stability for imaging of NTS_1 receptor-expressing tumors. *Cancers* **2022**, *14*, 4922.

(48) Schindler, L.; Wohlfahrt, K.; Gluhacevic von Krüchten, L.; Prante, O.; Keller, M.*; Maschauer, S.* Neurotensin analogs by fluoroglycosylation at N^{ω}-carbamoylated arginines for PET imaging of NTS_1-positive tumors. *Sci. Rep.* **2022**, *12*, 15028.

(47) Tang, T.; Tan, Q.; Han, S.; Diemar, A.; Lobner, K.; Wang, H.; Schuss, C.; Behr, V.; Morl, K.; Wang, M.; Chu, X.; Yi, C.; Keller, M.; Kofoed, J.; Reedtz-Runge, S.; Kaiser, A.*; Beck-Sickinger, A. G.*; Zhao, Q.*; Wu, B.* Receptor-specific recognition of NPY peptides revealed by structures of NPY receptors. *Sci. Adv.* **2022**, *8*, eabm1232.

(46) Tahk, M. J.; Torp, J.; Ali, M. A. S.; Fishman, D.; Parts, L.; Gratz, L.; Müller, C.; Keller, M.; Veiksina, S.; Laasfeld, T.*; Rinken, A.* Live-cell microscopy or fluorescence anisotropy with budded baculoviruses-which way to go with measuring ligand binding to M_4 muscarinic receptors? *Open Biol.* **2022**, *12*, 220019.

(45) Müller, C.; Gleixner, J.; Tahk, M. J.; Kopanchuk, S.; Laasfeld, T.; Weinhart, M.; Schollmeyer, D.; Betschart, M. U.; Lüdeke, S.; Koch, P.; Rinken, A.; Keller, M.* Structure-based design of high-affinity fluorescent probes for the neuropeptide Y Y_1 receptor. *J. Med. Chem.* **2022**, *65*, 4832-4853.

2021

(44) Konieczny, A.; Conrad, M.; Ertl, F. J.; Gleixner, J.; Gattor, A. O.; Grätz, L.; Schmidt, M. F.; Neu, E.; Horn, A. H. C.; Wifling, D.; Gmeiner, P.; Clark, T.; Sticht, H.; Keller, M.* N-Terminus to arginine side-chain cyclization of linear peptidic neuropeptide Y Y_4 receptor ligands results in picomolar binding constants. *J. Med. Chem.* **2021**, *64*, 16746-16769.

(43) Weinhart, C. G.; Wifling, D.; Schmidt, M. F.; Neu, E.; Höring, C.; Clark, T.; Gmeiner, P.; Keller, M.* Dibenzodiazepinone-type muscarinic receptor antagonists conjugated to basic peptides:

impact of the linker moiety and unnatural amino acids on M_2R selectivity. *Eur. J. Med. Chem.* **2021**, *213*, 113159.

(42) Grätz, L.; Laasfeld, T.; Allikalt, A.; Gruber, C. G.; Pegoli, A.; Tahk, M. J.; Tsernant, M. L.; Keller, M.; Rinken, A. BRET- and fluorescence anisotropy-based assays for real-time monitoring of ligand binding to M_2 muscarinic acetylcholine receptors. Biochim. *Biophys. Acta Mol. Cell Res.* **2021**, *1868*, 118930.

2020

(41) Konieczny, A.; Braun, D.; Wifling, D.; Bernhardt, G.; Keller, M.* Oligopeptides as neuropeptide Y Y_4 receptor ligands: identification of a high-affinity tetrapeptide agonist and a hexapeptide antagonist. *J. Med. Chem.* **2020**, *63*, 8198-8215.

(40) Biselli, S.; Alencastre, I.; Tropmann, K.; Erdmann, D.; Chen, M.; Littmann, T.; Maia, A. F.; Gomez-Lazaro, M.; Tanaka, M.; Ozawa, T.; Keller, M.; Lamghari, M.; Buschauer, A.; Bernhardt, G. Fluorescent H_2 receptor squaramide-type antagonists: synthesis, characterization, and applications. *ACS Med. Chem. Lett.* **2020**, *11*, 1521-1528.

(39) Gruber, C. G.; Pegoli, A.; Müller, C.; Grätz, L.; She, X.; Keller, M.* Differently fluorescence-labelled dibenzodiazepinone-type muscarinic acetylcholine receptor ligands with high M_2R affinity. *RSC Med. Chem.* **2020**, *11*, 823-832.

(38) She, X.; Pegoli, A.; Gruber, C. G.; Wifling, D.; Carpenter, J.; Hübner, H.; Chen, M.; Wan, J.; Bernhardt, G.; Gmeiner, P.; Holliday, N. D.*; Keller, M.* Red-emitting dibenzodiazepinone derivatives as fluorescent dualsteric probes for the muscarinic acetylcholine M_2 receptor. *J. Med. Chem.* **2020**, *63*, 4133-4154.

(37) Buschmann, J.; Seiler, T.; Bernhardt, G.; Keller, M.; Wifling, D. Argininamide-type neuropeptide Y Y_1 receptor antagonists: the nature of N^{ω}-carbamoyl substituents determines Y_1R binding mode and affinity. *RSC Med. Chem.* **2020**, *11*, 274-282.

(36) Keller, M.*; Mahuroof, S. A.; Hong Yee, V.; Carpenter, J.; Schindler, L.; Littmann, T.; Pegoli, A.; Hübner, H.; Bernhardt, G.; Gmeiner, P.; Holliday, N. D.* Fluorescence labeling of neurotensin(8-13) via arginine residues gives molecular tools with high receptor affinity. *ACS Med. Chem. Lett.* **2020**, *11*, 16-22.

(35) Spinnler, K.; von Krüchten, L.; Konieczny, A.; Schindler, L.; Bernhardt, G.; Keller, M.* An alkyne-functionalized arginine for solid-phase synthesis enabling “bioorthogonal” peptide conjugation. *ACS Med. Chem. Lett.* **2020**, *11*, 334-339.

2019

(34) Gergs, U.; Bernhardt, G.; Buchwalow, I. B.; Edler, H.; Froba, J.; Keller, M.; Kirchhefer, U.; Kohler, F.; Misslinger, N.; Wache, H.; Neumann, J. Initial characterization of transgenic mice overexpressing human histamine H_2 receptors. *J. Pharmacol. Exp. Ther.* **2019**, *369*, 129-141.

(33) Lachmann, D.; Konieczny, A.; Keller, M.*; König, B.* Photochromic peptidic NPY Y_4 receptor ligands. *Org. Biomol. Chem.* **2019**, *17*, 2467-2478.

(32) Pegoli, A.; Wifling, D.; Gruber, C. G.; She, X.; Hübner, H.; Bernhardt, G.; Gmeiner, P.; Keller, M.* Conjugation of short peptides to dibenzodiazepinone-type muscarinic acetylcholine receptor ligands determines M_2R selectivity. *J. Med. Chem.* **2019**, *62*, 5358-5369.

(31) Schindler, L.; Bernhardt, G.; Keller, M.* Modifications at Arg and Ile give neurotensin(8-13) derivatives with high stability and retained NTS_1 receptor affinity. *ACS Med. Chem. Lett.* **2019**, *10*, 960-965.

(30) Maschauer, S.; Ott, J. J.; Bernhardt, G.; Kuwert, T.; Keller, M.; Prante, O. ^{18}F-labelled triazolyl-linked argininamides targeting the neuropeptide Y Y_1R for PET imaging of mammary carcinoma. *Sci. Rep.* **2019**, *9*, 1-12.

2018

(29) Yang, Z.; Han, S.; Keller, M.*; Kaiser, A.; Bender, B. J.; Bosse, M.; Burkert, K.; Kogler, L. M.; Wifling, D.; Bernhardt, G.; Plank, N.; Littmann, T.; Schmidt, P.; Yi, C.; Li, B.; Ye, S.; Zhang, R.; Xu, B.; Larhammar, D.; Stevens, R. C.; Huster, D.; Meiler, J.; Zhao, Q.; Beck-Sickinger, A. G.*; Buschauer, A.; Wu, B.* Structural basis of ligand binding modes at the neuropeptide Y Y_1 receptor. *Nature* **2018**, *556*, 520-524.

(28) Pockes, S.; Wifling, D.; Keller, M.; Buschauer, A.; Elz, S. Highly potent, stable, and selective dimeric hetarylpropylguanidine-type histamine H_2 receptor agonists. *ACS Omega* **2018**, *3*, 2865-2882.

2017

(27) She, X.; Pegoli, A.; Mayr, J.; Hübner, H.; Bernhardt, G.; Gmeiner, P.; Keller, M.* Heterodimerization of dibenzodiazepinone-type muscarinic acetylcholine receptor ligands leads to increased M_2R affinity and selectivity. *ACS Omega* **2017**, *2*, 6741-6754.

(26) Kuhn, K. K.; Littmann, T.; Dukorn, S.; Tanaka, M.; Keller, M.; Ozawa, T.; Bernhardt, G.; Buschauer, A. In search of NPY Y_4R antagonists: Incorporation of carbamoylated arginine, aza-amino acids, or D-amino acids into oligopeptides derived from the C-termini of the endogenous agonists. *ACS Omega* **2017**, *2*, 3616-3631.

(25) Pegoli, A.; She, X.; Wifling, D.; Hübner, H.; Bernhardt, G.; Gmeiner, P.; Keller, M.* Radiolabeled dibenzodiazepinone-type antagonists give evidence of dualsteric binding at the M_2 muscarinic acetylcholine receptor. *J. Med. Chem.* **2017**, *60*, 3314-3334.

(24) Dukorn, S.; Littmann, T.; Keller, M.; Kuhn, K.; Cabrele, C.; Baumeister, P.; Bernhardt, G.; Buschauer, A. Fluorescence- and radiolabeling of [Lys^4,$Nle^{17,30}$]hPP yields molecular tools for the NPY Y_4 receptor. *Bioconjug. Chem.* **2017**, *28*, 1291-1304.

(23) Keller, M.*; Maschauer, S.; Brennauer, A.; Tripal, P.; Koglin, N.; Dittrich, R.; Bernhardt, G.; Kuwert, T.; Wester, H. J.; Buschauer, A.; Prante, O.* Prototypic ^{18}F-labeled argininamide-type neuropeptide Y Y_1R antagonists as tracers for PET imaging of mammary carcinoma. *ACS Med. Chem. Lett.* **2017**, *8*, 304-309.

2016

(22) Kuhn, K. K.; Ertl, T.; Dukorn, S.; Keller, M.; Bernhardt, G.; Reiser, O.; Buschauer, A. High affinity agonists of the neuropeptide Y (NPY) Y_4 receptor derived from the C-terminal pentapeptide of human pancreatic polypeptide (hPP): Synthesis, stereochemical discrimination, and radiolabeling. *J. Med. Chem.* **2016**, *59*, 6045-6058.

(21) Keller, M.*; Kuhn, K. K.; Einsiedel, J.; Hübner, H.; Biselli, S.; Mollereau, C.; Wifling, D.; Svobodová, J.; Bernhardt, G.; Cabrele, C.; Vanderheyden, P. M. L.; Gmeiner, P.; Buschauer, A. Mimicking of arginine by functionalized N^{ω}-carbamoylated arginine as a new broadly applicable approach to labeled bioactive peptides: high affinity angiotensin, neuropeptide Y, neuropeptide FF and neurotensin receptor ligands as examples. *J. Med. Chem.* **2016**, *59*, 1925-1945.

2015

(20) Keller, M.*; Weiss, S.; Hutzler, C.; Kuhn, K. K.; Mollereau, C.; Dukorn, S.; Schindler, L.; Bernhardt, G.; Koenig, B.; Buschauer, A. N^{ω}-Carbamoylation of the argininamide moiety: an

avenue to insurmountable NPY Y_1 receptor antagonists and a radiolabeled selective high-affinity molecular tool ([^{3}H]UR-MK299) with extended residence time. *J. Med. Chem.* **2015**, *58*, 8834-8849.

(19) Keller, M.*; Trankle, C.; She, X.; Pegoli, A.; Bernhardt, G.; Buschauer, A.; Read, R. W.* M_2 Subtype preferring dibenzodiazepinone-type muscarinic receptor ligands: effect of chemical homo-dimerization on orthosteric (and allosteric?) binding. *Bioorg. Med. Chem.* **2015**, *23*, 3970-3990.

(18) Keller, M.*; Schindler, L.; Bernhardt, G.; Buschauer, A. Toward labeled argininamide-type NPY Y_1 receptor antagonists: identification of a favorable propionylation site in BIBO3304. *Arch. Pharm.* **2015**, *348*, 390-398.

(17) Kagermeier, N.; Werner, K.; Keller, M.; Baumeister, P.; Bernhardt, G.; Seifert, R.; Buschauer, A. Dimeric carbamoylguanidine-type histamine H_2 receptor ligands: A new class of potent and selective agonists. *Bioorg. Med. Chem.* **2015**, *23*, 3957-3969.

2013

(16) Keller, M.; Kaske, M.; Holzammer, T.; Bernhardt, G.; Buschauer, A. Dimeric argininamide-type neuropeptide Y receptor antagonists: Chiral discrimination between Y_1 and Y_4 receptors. *Bioorg. Med. Chem.* **2013**, *21*, 6303-6322.

(15) Pluym, N.; Baumeister, P.; Keller, M.; Bernhardt, G.; Buschauer, A. [^{3}H]UR-PLN196: a selective nonpeptide radioligand and insurmountable antagonist for the neuropeptide Y Y(2) receptor. *ChemMedChem* **2013**.

2012

(14) Keller, M.; Bhadbhade, M. M.; Read, R. W. Two dibenzodiazepinone molecules with dissimilar dimeric associations and apparent different tautomeric forms. *Acta Crystallogr., Sect. C Cryst. Struct. Commun.* **2012**, *C68*, o240-o246.

(13) Memminger, M.; Keller, M.; Lopuch, M.; Pop, N.; Bernhardt, G.; von Angerer, E.; Buschauer, A. The neuropeptide Y Y_1 receptor: a diagnostic marker? Expression in MCF-7 breast cancer cells is down-regulated by antiestrogens in vitro and in xenografts. *PLoS One* **2012**, *7*, e51032.

2011

(12) Keller, M.; Bernhardt, G.; Buschauer, A. [^{3}H]UR-MK136: A highly potent and selective radioligand for neuropeptide Y Y_1 receptors. *ChemMedChem* **2011**, *6*, 1566-1571.

(11) Keller, M.; Erdmann, D.; Pop, N.; Pluym, N.; Teng, S.; Bernhardt, G.; Buschauer, A. Red-fluorescent argininamide-type NPY Y_1 receptor antagonists as pharmacological tools. *Bioorg. Med. Chem.* **2011**, *19*, 2859-2878.

(10) Pluym, N.; Brennauer, A.; Keller, M.; Ziemek, R.; Pop, N.; Bernhardt, G.; Buschauer, A. Application of the guanidine-acylguanidine bioisosteric approach to argininamide-type NPY Y_2 receptor antagonists. *ChemMedChem* **2011**, *6*, 1727-1738.

2010

(9) Kleinmaier, R.; Keller, M.; Igel, P.; Buschauer, A.; Gschwind, R. M. Conformations, conformational preferences, and conformational exchange of N'-substituted N-acylguanidines: intermolecular interactions hold the key. *J. Am. Chem. Soc.* **2010**, *132*, 11223-11233.

(8) Hild, W.; Pollinger, K.; Caporale, A.; Cabrele, C.; Keller, M.; Pluym, N.; Buschauer, A.; Rachel, R.; Tessmar, J.; Breunig, M.; Goepferich, A. G protein-coupled receptors function as logic gates for nanoparticle binding and cell uptake. *Proc. Natl. Acad. Sci. U. S. A.* **2010**, *107*, 10667-10672.

(7) Weiss, S.; Keller, M.; Bernhardt, G.; Buschauer, A.; Koenig, B. N^G-Acyl-argininamides as NPY Y_1 receptor antagonists: influence of structurally diverse acyl substituents on stability and affinity. *Bioorg. Med. Chem.* **2010**, *18*, 6292-6304.

2009

(6) Keller, M.; Teng, S.; Bernhardt, G.; Buschauer, A. Bivalent argininamide-type Neuropeptide Y Y_1 antagonists do not support the hypothesis of receptor dimerization. *ChemMedChem* **2009**, *4*, 1733-1745.

2008

(5) Keller, M.; Pop, N.; Hutzler, C.; Beck-Sickinger, A. G.; Bernhardt, G.; Buschauer, A. Guanidine-acylguanidine bioisosteric approach in the design of radioligands: synthesis of a tritium-labeled N^G-propionylargininamide ([^{3}H]-UR-MK114) as a highly potent and selective neuropeptide Y Y_1 receptor antagonist. *J. Med. Chem.* **2008**, *51*, 8168-8172.

(4) Weiss, S.; Keller, M.; Bernhardt, G.; Buschauer, A.; König, B. Modular synthesis of non-peptidic bivalent NPY Y_1 receptor antagonists. *Bioorg. Med. Chem.* **2008**, *16*, 9858-9866.

(3) Ghorai, P.; Kraus, A.; Keller, M.; Gotte, C.; Igel, P.; Schneider, E.; Schnell, D.; Bernhardt, G.; Dove, S.; Zabel, M.; Elz, S.; Seifert, R.; Buschauer, A. Acylguanidines as bioisosteres of guanidines: N^G-acylated imidazolylpropylguanidines, a new class of histamine H_2 receptor agonists. *J. Med. Chem.* **2008**, *51*, 7193-7204.

2007

(2) Schneider, E.; Keller, M.; Brennauer, A.; Hoefelschweiger, B. K.; Gross, D.; Wolfbeis, O. S.; Bernhardt, G.; Buschauer, A. Synthesis and characterization of the first fluorescent nonpeptide NPY Y_1 receptor antagonist. *Chembiochem* **2007**, *8*, 1981-1988.

(1) Brennauer, A.; Keller, M.; Freund, M.; Bernhardt, G.; Buschauer, A. Decomposition of 1-(ω-aminoalkanoyl)guanidines under alkaline conditions. *Tetrahedron Lett.* **2007**, *48*, 6996-6999.